Page last updated: 2024-08-24

topotecan and Carcinoma, Small Cell

topotecan has been researched along with Carcinoma, Small Cell in 137 studies

Research

Studies (137)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	24 (17.52)	18.2507
2000's	100 (72.99)	29.6817
2010's	13 (9.49)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bauer, F; Rao, V; Vredenburgh, JJ	1
Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G	1
Bonfill Cosp, X; Cortés-Jofré, M; Pelayo Alvarez, M; Westeel, V	1
Hamilton, G	1
Allen, J; Gandara, DR; Gitlitz, B; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ	1
Havlioglu, N; Hueser, CN; Nguyen, NC; Osman, M; Patel, AJ	1
Gomi, K; Hommura, F; Inage, M; Inoue, A; Inoue, C; Ishimoto, O; Maemondo, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T; Takanashi, S; Tsukamoto, T; Watanabe, H; Yamazaki, K; Yokouchi, H	1
Adjei, AA; Bryce, AH; Hillman, SL; Jett, JR; Kugler, JW; Mattar, B; Perez, EA; Rowland, K; Soori, G; Wender, DB	1
Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L	1
Biernacka, B; Buczkowski, J; Krawczyk, P; Milanowski, J; Perzyło, K; Siwiec, A	1
Burris, HA; Clark, BL; Gandhi, JG; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Peyton, JD; Spigel, DR; Vazquez, ER; West-Osterfield, K	1
Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L	1
Arrowsmith, ER; Burris, HA; Clark, BL; Greco, FA; Hainsworth, JD; Shipley, DL; Spigel, DR; Whorf, RC	1
Cufer, T; Kern, I; Knez, L; Ovčariček, T; Sadikov, A; Sodja, E	1
Spigel, DR	1
Deppermann, M; Kaubitsch, S; Keppler, U; Korfel, A; Oehm, C; Thiel, E; von Pawel, J	1
Rowinsky, EK	1
Chak, K; Chan, AT; Johnson, P; Lee, TW; Leung, TW; Mok, TS; Wong, H; Yeo, W; Yim, A; Yu, KH; Zee, B	1
Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P	1
Beriwal, S; Garcia-Young, JA; Singh, S	1
Agelaki, S; Androulakis, N; Apostolopoulou, F; Blazoyiannakis, G; Georgoulias, V; Kakolyris, S; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Pavlakou, G; Samonis, G; Vardakis, N; Veslemes, M	1
Ardizzoni, A; Bosquee, L; Buchholz, E; Debruyne, C; Gaafar, R; King, K; Legrand, C; Lianes, P; Manegold, C; Neumaier, C; Smit, EF; ten Velde, G	1
Birch, R; Campos, L; Hainsworth, J; Schnell, F; Tongol, J; West, W	1
Sandler, AB	1
Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF	1
Chiappori, A; Rocha Lima, CM	1
Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM	1
Bauman, MD; Ebbert, LP; Kugler, JW; Mahoney, MR; Mailliard, JA; Marks, RS; Schaefer, PL; Sloan, JA; Tazelaar, HD; Wiesenfeld, M	1
Baselga, J; Carrato, A; Domine, M; Felip, E; Font, A; Garrido, P; Mañe, JM; Rosell, R; Santomé, L; Terrasa, J; Vadell, C	1
von Pawel, J	1
Greco, FA	1
Treat, J	1
Beaulieu, N; Blum, K; Byrd, B; Davies, M; Hobdy, EM; Kraut, E; Masters, G; McKeon, A; Murren, JR	1
Campling, B	1
Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA	1
Huang, CH; Lane, SR; Levin, J; Treat, J	1
Reddy, K	1
Christodoulou, C; Deliyiannis, F; Malamos, NA; Rigatos, SK; Skarlos, DV; Stathopoulos, GP; Stathopoulos, JG	1
Hiraoka, N; Nakayama, M; Ohno, S; Takumi, C; Yamada, R; Yoshikawa, T	1
de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C	1
Stewart, DJ	2
Ardizzoni, A	1
Gralla, RJ	1
Eckardt, JR	2
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M	1
Buchholz, E; Gatzemeier, U; Goetz, E; Groth, G; Manegold, C; Reck, M	1
Fuhr, HG; Jensen, K; Keppler, U; Mueller, C; Neubauer, A; Schröder, M; Seifart, U; Staab, HJ; Ukena, J; Wolf, M	1
Hansen, LT; Kristjansen, PE; Lund, EL	1
Burger, H; Figg, WD; Gelderblom, H; Loos, WJ; Nooter, K; Sissung, TM; Sparreboom, A; Verweij, J	1
Breton, JL; Cardenal, F; Gervais, R; Lymboura, M; Mattson, K; Preston, A; Quoix, E; Ross, G; Schramel, F; Wilson, J	1
Bafaloukos, D; Briasoulis, E; Christodoulou, C; Kalofonos, HP; Koutras, A; Makatsoris, T; Samantas, E; Skarlos, DV	1
Antoniou, D; Armenaki, O; Athanasiadis, A; Christodoulou, Ch; Dimitroulis, J; Georgatou, N; Giamboudakis, P; Giannakakis, T; Katis, K; Rigatos, SK; Skarlos, D; Stathopoulos, GP; Stathopoulos, J	1
Donahue, A; Faucette, S; Gillenwater, HH; Kirstein, MN; Lindley, C; McCune, JS; Moore, D; Shord, S; Socinski, MA; Stewart, CF; Zamboni, WC	1
Armstrong, DK; Lane, S; Levin, J; Poulin, R; Spriggs, D	1
Penson, RT; Seiden, MV	1
Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS	1
Agelidou, A; Agelidou, M; Boukovinas, J; Georgoulias, V; Gerogianni, A; Ignatiadis, M; Mavroudis, D; Nikolakopoulos, J; Pavlakou, G; Syrigos, K; Tselepatiotis, E; Veslemes, M	1
Buller, R; Crawford, J; Garst, J; Lane, S	1
Gosse, H; Huber, RM; Kleinschmidt, R; Mezger, J; Reck, M; Saal, JG; Steppert, C; Steppling, H; von Pawel, J	1
Perry, MC	1
Brannon, S; Crofts, TE; Eckardt, JR; Papai, Z; Ross, G; Tomova, A; Tzekova, V; von Pawel, J; Wissel, P	1
Fournel, P	1
Pujol, JL	1
Bernath, AM; Carroll, TJ; Foster, N; Hillman, S; Jett, JR; Lair, BS; Mailliard, JA; Molina, JR; Nikcevich, D; Tazelaar, HD	1
Harita, S; Hotta, K; Kiura, K; Kuyama, S; Nogami, N; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Tada, A; Takigawa, N; Tanimoto, M; Ueoka, H	1
Abrahams, C; Caligiuri, P; Desai, AA; Hogarth, DK; Maitland, ML; Salgia, R; Wilcox, R	1
Huber, RM; Kaubitzsch, S; Lane, S; Lilenbaum, RC; Masters, G; Treat, J; Wissel, P	1
Al Omari, A; Case, D; Miller, AA; Murry, DJ	1
Dethling, J; Fink, T; Hans, K; Koschel, G; Lorenz, R; Mueller, C; Schade-Brittinger, C; Schroeder, H; Seifart, U; Wolf, M	1
Ciuleanu, TE; Crofts, T; Cuceviá, B; Dane, GC; Juhasz, G; O'Brien, ME; Ross, GA; Shparyk, Y; Thatcher, N; Tsekov, H	1
Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T	1
Garst, J	1
Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB	1
Nelson, R	1
Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E	1
Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C	1
Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D	1
Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D	1
Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR	1
Ettinger, DS	2
Ardizzoni, A; Dane, G; Eckardt, JR; Papai, Z; Poulin, R; Preston, AJ; Pujol, JL; Quoix, E; Ross, G; von Pawel, J	1
Nicum, SJ; O'Brien, ME	1
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH	1
Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF	1
Govindan, R; Morgensztern, D; Perry, MC	1
Jensen, BB; Jensen, PB; Johansen, J; Langer, SW; Lassen, U; Palshof, T; Sorensen, M	1
An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB	1
Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT	1
Carden, CP; O'Brien, ME	1
Jensen, PB; Sehested, M; Sorensen, M	1
Kim, K	1
Beijnen, JH; Creemers, GJ; Davies, B; de Boer-Dennert, M; McDonald, M; Rosing, H; Schellens, JH; Verweij, J	1
Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J	1
Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM	1
Broom, C	1
Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M	1
Ardizzoni, A; Dombernowsky, P; Gamucci, T; Giaccone, G; Hansen, H; Kaplan, S; Postmus, P; Schaefer, B; Verweij, J; Wanders, J	1
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A	1
Negoro, S	2
Schiller, JH	3
Ghaemmaghami, M; Jett, JR	1
Beijnen, JH; Herben, VM; Hudson, I; Schot, ME; ten Bokkel Huinink, WW	1
Carmichael, J; Chrysson, NG; Clark, PI; Depierre, A; Fields, SZ; Gralla, R; Kleisbauer, JP; Krebs, JB; Lane, SR; Palmer, MC; Ross, G; Schiller, JH; Shepherd, FA; Stewart, DJ; von Pawel, J	1
Ormrod, D; Spencer, CM	1
Ascari, E; Brugnatelli, S; Comolli, G; Danova, M; Ferrari, S; Porta, C; Pugliese, P; Riccardi, A	1
Cesano, A; Fields, SZ; Lane, SR; Poulin, R; Ross, G	1
Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T	1
Kelly, K	2
Sandler, A	1
Hansen, HH; Herrstedt, J; Hirsch, FR; Jensen, PB; Sorensen, M	1
Bildat, S; Camlett, I; Gatzemeier, U; Lane, S; Moreau, L; Pujol, JL; Ranson, M; Richardson, G; Rivière, A; Ross, G; Steppert, C; von Pawel, J	1
Adak, S; Cella, D; DeVore, RF; Johnson, DH; Schiller, JH	1
Brunetti, C; Carreca, I; Comella, G; Comella, P; DeCataldis, G; Frasci, G; Muci, D; Natale, M; Nicolella, G; Palmeri, S; Panza, N; Piantedosi, F; Russo, A	1
Chastagner, P; Kozin, SV; Taghian, A	1
Burris, HA; Greco, FA; Hainsworth, JD	1
Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Palamidas, P; Raptis, A	1
Huang, CH; Treat, J	1
Clark, PI; Hannigan, K; Marshall, E; O'Neill, P; Ross, G; Smith, D	1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N	1
Feng, F; He, X; Shi, Y	1
Giaccone, G; Huisman, C; Postmus, PE; Smit, EF	1
Kato, Y; Saijo, N	1
Burris, HA; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Morrissey, LH; Prasthofer, EF; Scullin, DC	1
Bando, H; Sano, T; Ueda, H	1
Ariyoshi, Y; Sugiura, T	1

Reviews

33 review(s) available for topotecan and Carcinoma, Small Cell

Article	Year
Refractory Small Cell Carcinoma of the Ovary - Hypercalcemic Type (SCCOHT) Treated with Romidepsin and Topotecan: A Case Report and Review of the Literature. Connecticut medicine, 2016, Volume: 80, Issue:9 Topics: Antibiotics, Antineoplastic; Carcinoma, Small Cell; Depsipeptides; Disease Progression; Fatal Outcome; Female; Humans; Ovarian Neoplasms; Ovariectomy; Topoisomerase I Inhibitors; Topotecan; Young Adult	2016
Chemotherapy versus best supportive care for extensive small cell lung cancer. The Cochrane database of systematic reviews, 2013, Nov-27, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan	2013
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? The oncologist, 2002, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Topotecan; Treatment Outcome	2002
Chemotherapy for small cell lung cancer. Seminars in oncology, 2003, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan	2003
Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 40, Issue:3 Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Analysis; Topotecan	2003
Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. The oncologist, 2004, Volume: 9, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Feasibility Studies; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Topotecan	2004
Evolving role of topotecan in treating small-cell lung cancer. Clinical lung cancer, 2004, Volume: 5, Issue:5 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Topotecan	2004
[A case of brain metastasis of small cell lung cancer improved with nogitecan hydrochloride (topotecan) after prophylactic irradiation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7 Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Tomography, X-Ray Computed; Topotecan	2004
In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. International journal of cancer, 2005, Feb-20, Volume: 113, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous	2005
Topotecan in the treatment of recurrent small cell lung cancer: an update. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2004
Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Palliative Care; Quality of Life; Topotecan	2004
Emerging role of weekly topotecan in recurrent small cell lung cancer. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2004
Topotecan in the first-line treatment of small cell lung cancer. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Humans; Lung Neoplasms; Topotecan	2004
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topotecan	2005
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert opinion on drug safety, 2007, Volume: 6, Issue:1 Topics: Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2007
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lomustine; Lung Neoplasms; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Practice Guidelines as Topic; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Topotecan	2007
Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:2 Topics: Anthracyclines; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Europe; Humans; Japan; Lung Neoplasms; Topotecan; United States	2007
Topotecan for the treatment of small-cell lung cancer. Expert review of anticancer therapy, 2007, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Topotecan	2007
New drugs for treating small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan	1995
Clinical studies of topotecan. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
["State-of-the-art" chemotherapy for small-cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine	1997
Topotecan in small cell lung cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Topoisomerase I Inhibitors; Topotecan	1997
New agents in the treatment of small cell lung cancer. Chest, 1998, Volume: 113, Issue:1 Suppl Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	1998
Topotecan: a review of its efficacy in small cell lung cancer. Drugs, 1999, Volume: 58, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; In Vitro Techniques; Lung Neoplasms; Topotecan	1999
New chemotherapy agents for small cell lung cancer. Chest, 2000, Volume: 117, Issue:4 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine	2000
Extensive small-cell lung cancer: a treatment overview. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:7 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	2000
Treatment of extensive stage small cell lung cancer. Cancer treatment and research, 2001, Volume: 105 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan	2001
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology, 2001, Volume: 61 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Male; Prognosis; Survival Analysis; Topotecan; Treatment Outcome	2001
Future role of topotecan in the treatment of lung cancer. Oncology, 2001, Volume: 61 Suppl 1 Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Forecasting; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Survival Analysis; Topotecan; Treatment Outcome	2001
[Developed new agents for lung cancer]. Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine	2002
[Nogitecan hydrochloride]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan	2002
[DNA topoisomerase inhibitor]. Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan	1992

Trials

63 trial(s) available for topotecan and Carcinoma, Small Cell

Article	Year
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clinical lung cancer, 2016, Volume: 17, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Databases, Factual; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Outcome Assessment; Platinum Compounds; Prognosis; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis; Therapies, Investigational; Topotecan; Treatment Outcome; Young Adult	2016
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-20, Volume: 26, Issue:33 Topics: Aged; Anthracyclines; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan	2008
Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. American journal of clinical oncology, 2010, Volume: 33, Issue:4 Topics: Administration, Oral; Adult; Aged; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors; Topotecan; Treatment Outcome	2010
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesylates; Middle Aged; Patient Selection; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Topotecan	2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan	2010
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan	2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clinical lung cancer, 2011, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	2011
Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Disease Progression; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Prospective Studies; Survival Analysis; Topotecan	2002
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer, 2002, Oct-01, Volume: 95, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan	2002
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 38, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome	2002
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:1 Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Topotecan; Treatment Outcome	2003
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Time Factors; Topotecan	2003
Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. The oncologist, 2003, Volume: 8, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Topotecan; Treatment Outcome	2003
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer, 2003, May-15, Volume: 97, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome	2003
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan	2003
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. American journal of clinical oncology, 2003, Volume: 26, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome	2003
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2003
A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. Cancer biology & therapy, 2004, Volume: 3, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis; Survivors; Time Factors; Topotecan; Treatment Outcome	2004
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2004
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	2004
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan	2005
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Topotecan; Treatment Outcome	2005
Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome	2006
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Male; Middle Aged; Paclitaxel; Topotecan	2006
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Cancer investigation, 2005, Volume: 23, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Topotecan; Treatment Outcome	2005
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. The oncologist, 2005, Volume: 10, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan	2005
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan	2005
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. The European respiratory journal, 2006, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Neutrophils; Organoplatinum Compounds; Platelet Count; Retreatment; Survival Rate; Topotecan; Treatment Outcome	2006
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Topotecan	2006
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. American journal of clinical oncology, 2006, Volume: 29, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan; Treatment Outcome	2006
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carcinoma, Small Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome	2006
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2006
Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Small Cell; Central Nervous System Neoplasms; Cisplatin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Time Factors; Topotecan; Treatment Outcome	2007
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-01, Volume: 24, Issue:34 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Survival Rate; Topotecan	2006
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clinical drug investigation, 2006, Volume: 26, Issue:5 Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome	2006
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan	2007
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting	2007
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan	2006
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan	2006
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-20, Volume: 25, Issue:15 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Rate; Topotecan	2007
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome	2007
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Topotecan; Treatment Failure	2008
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Conformal; Topotecan	2008
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan	2008
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. British journal of cancer, 1996, Volume: 73, Issue:10 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Carcinoma, Small Cell; Colonic Neoplasms; Cross-Over Studies; Female; Humans; Hydroxy Acids; Lactones; Male; Metabolic Clearance Rate; Middle Aged; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan	1996
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States	1996
[Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995]. Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:6 Suppl Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Dr Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Humans; Lung Neoplasms; Remission Induction; Survival Analysis; Topotecan	1997
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anti-cancer drugs, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Small Cell; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting	1998
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Topotecan; Vincristine	1999
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	2000
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neutropenia; Topotecan; Treatment Outcome	2001
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Topotecan; Treatment Outcome	2001
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. British journal of cancer, 2001, May-04, Volume: 84, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Topotecan	2001
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan	2001
A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. Oncology, 2001, Volume: 61 Suppl 1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome	2001
Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy. Oncology, 2001, Volume: 61 Suppl 1 Topics: Administration, Oral; Adult; Aged; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Topotecan; Treatment Outcome	2001
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology, 2001, Volume: 61, Issue:4 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2001
[Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Leukopoiesis; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Outcome	2001
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2001
Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer, 2002, May-01, Volume: 94, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Topotecan; Treatment Outcome	2002

Other Studies

41 other study(ies) available for topotecan and Carcinoma, Small Cell

Article	Year
[Analysis of drug therapy of lung cancer in Hungary]. Magyar onkologia, 2013, Volume: 57, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan	2013
Cytotoxic effects of fascaplysin against small cell lung cancer cell lines. Marine drugs, 2014, Mar-07, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Porifera; Reactive Oxygen Species; Topotecan	2014
Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World journal of surgical oncology, 2008, Sep-25, Volume: 6 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Craniotomy; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Topotecan	2008
[Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report]. Pneumonologia i alergologia polska, 2010, Volume: 78, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Poland; Proportional Hazards Models; Recurrence; Survival Analysis; Topotecan; Treatment Outcome	2010
Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:18 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pilot Projects; Prognosis; Retrospective Studies; Single-Blind Method; Slovenia; Topotecan; Treatment Outcome; Vincristine	2012
Treatment update in small-cell lung cancer: from limited to extensive disease. Current treatment options in oncology, 2012, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan	2012
Tumor lysis syndrome in extensive-stage small-cell lung cancer. American journal of clinical oncology, 2002, Volume: 25, Issue:5 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Small Cell; Enzyme Inhibitors; Fatal Outcome; Female; Humans; Lung Neoplasms; Topotecan; Tumor Lysis Syndrome	2002
The role of topotecan in treating small cell lung cancer: second-line treatment. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Administration, Oral; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan	2003
Topotecan as first-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan	2003
Weekly topotecan in the management of lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Humans; Lung Neoplasms; Topotecan	2003
Topotecan in small cell lung cancer: first or second line? Cancer biology & therapy, 2004, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Reproducibility of Results; Topotecan	2004
Foreword--new directions for topotecan in lung cancer treatment. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Lung Neoplasms; Quality of Life; Topotecan	2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer research, 2005, Feb-15, Volume: 65, Issue:4 Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan	2005
Augmenting tumor sensitivity to topotecan by transient hypoxia. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Small Cell; Cell Hypoxia; Cell Line, Tumor; Central Nervous System Neoplasms; Glioblastoma; Glucose Transporter Type 1; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Topotecan; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2005
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer biology & therapy, 2005, Volume: 4, Issue:6 Topics: Administration, Oral; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Carcinoma, Small Cell; DNA, Neoplasm; Female; Gene Frequency; Genotype; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Pharmacogenetics; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Topotecan; Tumor Cells, Cultured	2005
Topotecan: weighing in when there are many options. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Palliative Care; Topotecan	2005
Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2005
Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan	2006
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan	2006
[Is small cell lung cancer an orphan disease?]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine	2006
Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Dyspnea; Fatal Outcome; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pulmonary Alveoli; Pulmonary Fibrosis; Respiratory Insufficiency; Topotecan	2006
Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status. Clinical lung cancer, 2006, Volume: 8, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome	2006
Topotecan more effective than supportive care. The Lancet. Oncology, 2007, Volume: 8, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Survival Rate; Topotecan	2007
Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan	2007
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan	2008
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Current medical research and opinion, 2008, Volume: 24, Issue:4 Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine	2008
Small-cell lung cancer, getting smaller but still difficult to treat. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:2 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Humans; Lung Neoplasms; Radiotherapy, Adjuvant; Recurrence; Topotecan	2008
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. British journal of cancer, 1995, Volume: 72, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carbon Radioisotopes; Carcinoma, Small Cell; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1995
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests. Computer methods and programs in biomedicine, 1995, Volume: 46, Issue:2 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Etoposide; Feasibility Studies; Follow-Up Studies; Humans; Linear Models; Lung Neoplasms; Programming Languages; Research Design; Sensitivity and Specificity; Software; Survival Rate; Topotecan	1995
Topotecan demonstrates significant activity in small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Remission Induction; Topotecan	1996
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan	1996
Topotecan demonstrates significant activity in recurrent small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	1996
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. British journal of cancer, 1997, Volume: 75, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured	1997
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. International journal of cancer, 1997, Aug-07, Volume: 72, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water	1997
Evaluation of treatment of recurrent small-cell lung cancer. Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Humans; Lung Neoplasms; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Topotecan; Vincristine	1999
Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients. International journal of oncology, 1999, Volume: 15, Issue:4 Topics: Adult; Aged; Antigens, CD34; Apoptosis; Bromodeoxyuridine; Carcinoma, Small Cell; Cell Cycle; Drug Therapy, Combination; Erythropoietin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lung Neoplasms; Middle Aged; Platelet Count; Recombinant Proteins; Time Factors; Topotecan	1999
Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. International journal of oncology, 1999, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome	1999
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured	2000
Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. International journal of radiation oncology, biology, physics, 2001, Jul-01, Volume: 50, Issue:3 Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Small Cell; Combined Modality Therapy; Glioblastoma; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oxygen; Radiation Tolerance; Topotecan; Xenograft Model Antitumor Assays	2001
Novel therapies in lung cancer management. An update on the role of topotecan. Oncology, 2001, Volume: 61 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Prognosis; Topotecan; Treatment Outcome	2001
[A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Topotecan	2002